ArticleMolecular therapy. Advances2026
Impact of physical and chemical parameters on spinoculation for chimeric antigen receptor T cell manufacturing using a quality-by-design approach.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR) T cell therapies represent a significant advancement for treating hematological malignancies, particularly in relapsed/refractory cases. Despite their clinical success, the high cost of CAR T cell therapies remains a major barrier to broader implementation. A significant proportion of these costs stems from the dependency on viral vectors and the limited understanding of transduction mechanisms. This work evaluates the impact of physical and chemical parameters during transduction using a spinoculation process. Physical parameters, such as spinoculation duration and speed, were identified as key drivers of transduction efficiency, contributing to a 20%-30% increase in transduction. Similarly, the addition of LentiBOOST and polybrene enhanced transduction efficiency by approximately 1-2-fold compared with control conditions without these supplements. Given that both physical and chemical parameters influence transduction efficiency, a quality-by-design approach was used to systematically investigate their potential synergistic or antagonistic interactions. This systematic approach highlighted the cytotoxic impact of polybrene and demonstrated that LentiBOOST is critical to drive transduction, particularly in CD4 subsets. The optimized process led to a 2-3-fold improvement in transduction without compromising CAR T cell growth or functionality and was shown to be compatible with serum- and xeno-free medium, supporting its translational potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.